HALISTER: J&J 4Q Adj. EPS Beats Est.

J&J 4Q Adj. EPS Beats Est.

(Bloomberg) -- J&J 4Q adj. EPS $1.58, est. $1.56 (range $1.54-$1.62)
  • 4Q sales $18.1b, est. $18.3b (range $17.7b-$18.6b)
  • 4Q Remicade rev. $1.62b, est. $1.64b (Bloomberg data, average of 3)
    • 4Q Stelara rev. $879m, est. $881.7m
    • 4Q Xarelto rev. $598m, est. $559.7m
    • 4Q Imbruvica rev. $346m, est. $377m (average of 2)
    • 4Q Invokana rev. $371m, est. $387.7m
    • 4Q Olysio rev. $10m, est. $33m (1 est.)
  • 4Q worldwide medical devices sales $6.44b
  • Sees FY adj. EPS $6.93 to $7.08
NOTE:
  • 10 buys, 15 holds, 0 sells before today
  • Call 8:30am (NY time), 877-869-3847
Statement
Alert: HALISTER
Source: BFW (Bloomberg First Word)

Tickers
JNJ US (Johnson & Johnson)
MRK US (Merck & Co Inc)
4508 JP (Mitsubishi Tanabe Pharma Corp)

To de-activate this alert, click here

UUID: 7947283